Penumbra (PEN) vs Smith & Nephew SNATS (SNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Penumbra (PEN) has outperformed Smith & Nephew SNATS (SNN) over the past year, gaining 27.0% versus a loss of 24.7%. Over five years, PEN leads with a +18.2% price change compared with -24.0% for SNN. Penumbra is the larger company by market cap ($12.49 billion vs $11.21 billion), about 1.1 times the size.
On valuation, Smith & Nephew SNATS trades at a lower forward P/E (11.1x vs 51.7x for Penumbra). Smith & Nephew SNATS pays a dividend yielding 1.48%, while Penumbra does not currently pay one. Penumbra converts more of its revenue into profit, with a net margin of 12.7% versus 10.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PEN | SNN |
|---|---|---|
| Share price | $317.03 | $26.78 |
| Market cap | $12.49B | $11.21B |
| 1-day change | +0.21% | -0.41% |
| YTD return | +1.75% | -18.04% |
| 1-year return | +27.03% | -24.74% |
| 5-year return | +18.15% | -24.02% |
| P/E ratio (TTM) | 77.89 | 18.22 |
| Forward P/E | 51.70 | 11.11 |
| EPS (TTM) | $4.07 | $1.47 |
| Dividend yield | 0.00% | 1.48% |
| Annual dividend | $0.00 | $0.397 |
| Revenue (latest FY) | $1.40B | $6.16B |
| Revenue growth (YoY) | +17.50% | +6.09% |
| Net income (latest FY) | $177.69M | $625.00M |
| Gross margin | 67.14% | 68.01% |
| Operating margin | 13.48% | 12.88% |
| Net margin | 12.66% | 10.14% |
| 52-week high | $362.41 | $37.51 |
| 52-week low | $221.26 | $26.12 |
| Distance from 52-week high | -12.52% | -28.61% |
| Analyst consensus | hold | hold |
| Avg. price target upside | +14.05% | +20.69% |
| Average volume | 344.71K | 1.66M |
| Shares outstanding | 39.39M | 418.52M |
| Employees | 4,700 | 17,000 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PEN has outperformed SNN by 51.8 percentage points over the past year.
- Penumbra trades at a higher earnings multiple (77.9x vs 18.2x trailing P/E).
- Smith & Nephew SNATS offers a meaningfully higher dividend yield (1.48% vs 0.00%).
- Penumbra grew revenue faster in its latest fiscal year (+17.50% vs +6.09%).
About Penumbra
PEN stock →Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Health Care · Medical/Dental Instruments · 4,700 employees
About Smith & Nephew SNATS
SNN stock →Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Health Care · Industrial Specialties · 17,000 employees
PEN vs SNN FAQ
Which is bigger, Penumbra or Smith & Nephew SNATS?
Penumbra (PEN) is larger, with a market capitalization of $12.49B compared with $11.21B for Smith & Nephew SNATS (SNN).
Which stock has performed better over the past year, PEN or SNN?
PEN returned +27.03% over the past 12 months, compared with -24.74% for SNN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, PEN or SNN?
SNN has the lower trailing P/E at 18.2, versus 77.9 for PEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Penumbra or Smith & Nephew SNATS?
Smith & Nephew SNATS pays a dividend yielding 1.48%, while Penumbra does not currently pay a regular dividend.
Are Penumbra and Smith & Nephew SNATS in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Penumbra and Industrial Specialties for Smith & Nephew SNATS.